GRACE :: Lung Cancer

Moffitt Cancer Center

Is there a place for maintenance therapy in extensive stage SCLC?

Share

Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.


How should we integrate new immunotherapies into treatment strategies for lung cancer?

Share

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.


How do we approach acquired resistance to targeted therapies in lung cancer?

Share

Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.


What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

Share

Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

Discuss this post in the GRACE Discussion Forums


Can we target KRAS effectively in advanced NSCLC?

Share

Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

Discuss this post in the GRACE Discussion Forums


Could BRAF be a new target in NSCLC?

Share

Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.

Discuss this post in the GRACE Discussion Forums


Are molecular markers just for NSCLC?

Share

Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.

Discuss this post in the GRACE Discussion Forums


Is Nintedanib a new agent worthy of becoming a new treatment for advanced NSCLC?

Share

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

Discuss this post in the GRACE Discussion Forums


Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

Share

Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

Discuss this post in the GRACE Discussion Forums


Can we harness our immune system to fight NSCLC?

Share

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

Discuss this post in the GRACE Discussion Forums


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Other Resources